27.12.2023 - No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of . Seite 1
17.10.2023 - GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric . Seite 1
02.10.2023 - GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric . Seite 1
18.09.2023 - New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release formulation led to reversal of . Seite 1
07.09.2023 - Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales GARDEN CITY, New York, Sept. . Seite 1